Biomarin Historical Valuation
| BMRN Stock | USD 71.44 1.39 1.91% |
Some fundamental drivers such as market cap or Biomarin Pharmaceutical enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze Biomarin Pharmaceutical valuation indicators such as Working Capital of 0.0 or Enterprise Value of 9.8 B to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of Biomarin Pharmaceutical's future value.
Biomarin |
About Biomarin Valuation Data Analysis
Valuation is the financial process of determining what Biomarin Pharmaceutical is worth. Biomarin Pharmaceutical valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. Biomarin Pharmaceutical valuation ratios help investors to determine whether Biomarin Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biomarin with respect to the benefits of owning Biomarin Pharmaceutical security.
Biomarin Pharmaceutical Valuation Data Chart
Enterprise Value
Enterprise Value (or EV) is usually referred to as Biomarin Pharmaceutical theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Biomarin Pharmaceutical debt, but would also pocket its cash. Enterprise Value is more accurate representation of Biomarin Pharmaceutical value than its market capitalization because it takes into account all of Biomarin Pharmaceutical existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents. When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.25 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.